NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Phase 1

Active, not recruiting

Conditions: SARS-CoV-2 Infection

Interventions: Biological: B/HPIV3/S-6P

First Posted Date: 2023-09-07

Last Posted Date: 2024-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT06026514

Locations: 🇺🇸
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Phase 1

Recruiting

Conditions: Chronic HIV Infection

Interventions: Biological: 426c.Mod.Core-C4b
Other: Adjuvant 3M-052-AF+Alum

First Posted Date: 2023-08-23

Last Posted Date: 2024-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT06006546

Locations: 🇺🇸
New York Blood Center CRS (Site #31801), New York, New York, United States
🇺🇸
Birmingham, Birmingham, Alabama, United States
🇺🇸
Atlanta- Ponce, Atlanta, Georgia, United States

and more 7 locations

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Phase 2

Recruiting

Conditions: HIV I Infection

Interventions: Drug: Estradiol

First Posted Date: 2023-08-22

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT06005610

Locations: 🇺🇸
Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States
🇺🇸
Houston AIDS Research Team CRS (31473), Houston, Texas, United States
🇺🇸
UCSD Antiviral Research Center CRS (701), San Diego, California, United States

and more 27 locations

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

Phase 1

Recruiting

Conditions: Influenza

Interventions: Biological: VRC-FLUMOS0116-00-VP( FLUMos-v2)

First Posted Date: 2023-08-01

Last Posted Date: 2024-12-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT05968989

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Phase 2

Recruiting

Conditions: Immunization; Infection
Transplantation Infection
Influenza

Interventions: Biological: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological: High Dose Quadrivalent Inactivated Influenza Vaccine

First Posted Date: 2023-07-17

Last Posted Date: 2025-01-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 312

Registration Number: NCT05947071

Locations: 🇺🇸
Lucile Packard Children's Hospital Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Ann Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 5 locations

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Phase 1

Recruiting

Conditions: Influenza

Interventions: Biological: DCVC H1 HA mRNA vaccine
Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
Other: Sodium Chloride, 0.9%

First Posted Date: 2023-07-14

Last Posted Date: 2024-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT05945485

Locations: 🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Adults

Interventions: Drug: Bismuth subsalicylate

First Posted Date: 2023-07-05

Last Posted Date: 2024-10-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT05930197

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

Phase 2

Recruiting

Conditions: Kidney Transplant

Interventions: Biological: Abatacept
Procedure: Standard of Care at US Transplant Centers

First Posted Date: 2023-06-26

Last Posted Date: 2024-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 800

Registration Number: NCT05917522

Locations: 🇺🇸
University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States
🇺🇸
Cedars Sinai Medical Center: Transplantation, Los Angeles, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center: Transplantation, Los Angeles, California, United States

and more 12 locations

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults

Phase 1

Active, not recruiting

Conditions: Malaria

Interventions: Drug: Pvs230D1-EPA/Matrix-M

First Posted Date: 2023-06-22

Last Posted Date: 2024-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 59

Registration Number: NCT05913973

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

Phase 1

Active, not recruiting

Conditions: Hiv

Interventions: Drug: V3G CH848 Pr-NP1 60mcg
Drug: 3M-052-AF 5mcg
Drug: Alum 500 mcg
Drug: ACU-026-001-1 2.0mg
Drug: V3G CH848 mRNA-Tr2 50mcg
Drug: V3G CH848 Pr-NP1 100mcg

First Posted Date: 2023-06-15

Last Posted Date: 2024-02-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT05903339

Locations: 🇺🇸
Alabama CRS [Site ID: 31788], Birmingham, Alabama, United States
🇺🇸
Emory University School of Medicine, The Ponce de Leon Center CRS [Site ID: 5802], Atlanta, Georgia, United States
🇺🇸
Brigham & Women's Hospital [Site ID: 30007], Boston, Massachusetts, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy